ARS Pharmaceuticals, Inc.(SPRY)

$8.30▲0.19 (2.34%)

ARS Pharmaceuticals, Inc.(SPRY)

NASDAQ

$8.30▲0.19 (2.34%)

Overview Intelligence Chart Fundamentals Key Metrics Earnings Growth Analysts Financials Insiders Institutional

Analyst Sentiment

Analysts lean bullish — 40% recommend buying.

Consensus Rating

Buy

10 analysts·Moderate coverage

40%

Rating Distribution

Strong Buy

110%

Buy

330%

Hold

660%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 237% higher.

Bear Case

$26.00

+213%

Consensus

$28.00

+237%

Bull Case

$30.00

+261%

Price Range10 analysts

Low

Consensus

High

$26.00

$30.00

Current Target

Current Price

$8.30

Upside to Target

$19.70

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+81.59%

EPS—

FY2028

Rev+46.99%

EPS—

FY2029

Rev+36.09%

EPS+445.10%

Earnings Surprises

Recent Analyst Actions

Mar 10, 2026Leerink Partners

ARS Pharmaceuticals Inc (SPRY) PT Raised to $26 at Leerink Partners

Target:$26.00

+180.2%from $9.28

Nov 4, 2025Roth Capital

ARS Pharmaceuticals resumed with a Buy at Roth Capital

Target:$30.00

+256.5%from $8.41

Sep 26, 2025Raymond James

Raymond James positive on ARS Pharmaceuticals after weekly data

Target:$32.00

+230.4%from $9.69

Aug 19, 2024Cantor Fitzgerald

ARS Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald

Target:$30.00

+110.7%from $14.24

Aug 12, 2024Raymond James

ARS Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James

Target:$22.00

+102.8%from $10.85

Jul 25, 2024Raymond James

ARS Pharmaceuticals initiated with an Outperform at Raymond James

Target:$18.00

+73.1%from $10.40

Mar 5, 2024Leerink Partners

Leerink Partners Upgrades ARS Pharmaceuticals Inc (SPRY) to Outperform

Target:$18.00

+108.1%from $8.65

Dec 13, 2022Leerink Partners

SVB Leerink Initiates Coverage On ARS Pharmaceuticals with Outperform Rating, Announces Price Target of $14

Target:$14.00

+96.6%from $7.12

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance